Chardan Capital Reaffirms Buy Rating for Cognition Therapeutics (NASDAQ:CGTX)

Chardan Capital reiterated their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $11.00 price objective on the stock.

Other equities research analysts have also issued reports about the stock. HC Wainwright boosted their target price on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday, December 19th. B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $1.00 to $1.50 in a research note on Thursday, December 19th. Finally, Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Cognition Therapeutics currently has a consensus rating of “Buy” and an average target price of $8.30.

Cognition Therapeutics Trading Down 0.7 %

Shares of CGTX opened at $0.45 on Wednesday. The firm has a market cap of $18.90 million, a PE ratio of -0.47 and a beta of 0.96. The firm has a fifty day simple moving average of $0.68 and a two-hundred day simple moving average of $0.58. Cognition Therapeutics has a 1-year low of $0.34 and a 1-year high of $2.95.

Institutional Investors Weigh In On Cognition Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CGTX. BIOS Capital Management LP purchased a new stake in shares of Cognition Therapeutics in the 4th quarter worth $4,208,000. Voss Capital LP purchased a new stake in shares of Cognition Therapeutics in the 4th quarter worth $351,000. Sigma Planning Corp increased its stake in Cognition Therapeutics by 211.6% in the 4th quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock worth $431,000 after buying an additional 417,300 shares in the last quarter. Virtu Financial LLC purchased a new stake in Cognition Therapeutics in the 3rd quarter worth $27,000. Finally, Two Sigma Investments LP increased its stake in Cognition Therapeutics by 372.2% in the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock worth $38,000 after buying an additional 42,321 shares in the last quarter. 43.35% of the stock is currently owned by hedge funds and other institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.